These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8170559)

  • 41. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment.
    Guy RJ; Gilbey SG; Sheehy M; Asselman P; Watkins PJ
    Diabetologia; 1988 Apr; 31(4):214-20. PubMed ID: 3290018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes.
    Malone JI; Lowitt S; Salem AF; Miranda C; Korthals JK; Carver J
    Metabolism; 1996 Jul; 45(7):902-7. PubMed ID: 8692029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
    Ziegler D; Mayer P; Rathmann W; Gries FA
    Diabetes Res Clin Pract; 1991 Oct; 14(1):63-73. PubMed ID: 1748064
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Follow-up study of sensory-motor polyneuropathy in type 1 (insulin-dependent) diabetic subjects after simultaneous pancreas and kidney transplantation and after graft rejection.
    Müller-Felber W; Landgraf R; Wagner S; Mair N; Nusser J; Landgraf-Leurs MM; Abendroth A; Illner WD; Land W
    Diabetologia; 1991 Aug; 34 Suppl 1():S113-7. PubMed ID: 1936673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    J Diabetes Complications; 1992; 6(1):39-44. PubMed ID: 1562757
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Axonal transport and nerve conduction velocity in animal models of diabetic neuropathy.
    Tomlinson DR; Mayer JH
    Diabet Med; 1985 May; 2(3):210-2. PubMed ID: 2952422
    [No Abstract]   [Full Text] [Related]  

  • 48. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cone electroretinograms and visual acuities of diabetic patients on sorbinil treatment.
    Biersdorf WR; Malone JI; Pavan PR; Lowitt S
    Doc Ophthalmol; 1988 Jul; 69(3):247-54. PubMed ID: 3168726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model.
    Robison WG; Laver NM; Jacot JL; Glover JP
    Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2368-80. PubMed ID: 7591626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor.
    Sima AA; Nathaniel V; Prashar A; Bril V; Greene DA
    Diabetes; 1991 Sep; 40(9):1090-9. PubMed ID: 1936616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V; Buchanan RA
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
    Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
    Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.
    Boulton AJ; Levin S; Comstock J
    Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aldose reductase and the development of renal disease in diabetic dogs.
    Kern TS; Engerman RL
    J Diabetes Complications; 1999; 13(1):10-6. PubMed ID: 10232704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NIH testing sorbinil to prevent diabetic retinopathy.
    Marwick C
    JAMA; 1984 Sep; 252(10):1263. PubMed ID: 6433049
    [No Abstract]   [Full Text] [Related]  

  • 57. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    Diabet Med; 1993; 10 Suppl 2():44S-48S. PubMed ID: 8334842
    [No Abstract]   [Full Text] [Related]  

  • 58. Ranirestat for the management of diabetic sensorimotor polyneuropathy.
    Bril V; Hirose T; Tomioka S; Buchanan R;
    Diabetes Care; 2009 Jul; 32(7):1256-60. PubMed ID: 19366965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Fidarestat (SNK-860)].
    Hibi C
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():594-600. PubMed ID: 12387056
    [No Abstract]   [Full Text] [Related]  

  • 60. Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats.
    Beyer-Mears A; Murray FT; Del Val M; Cruz E; Sciadini M
    Pharmacology; 1988; 36(2):112-20. PubMed ID: 3127836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.